Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2916 Target Snapshot

Telomerase reverse transcriptase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,242Compounds
380Assays
2Approved Drugs
1,159.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Telomerase reverse transcriptase shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O14746. Start with anemia, then reuse UniProt O14746 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anemia, then reuse UniProt O14746 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
anemia

Telomerase reverse transcriptase shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with anemia because it currently carries approved-linked support. Linked drugs include IMETELSTAT SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Telomerase reverse transcriptase as ChEMBL target CHEMBL2916, mapped to UniProt O14746. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Telomerase reverse transcriptase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2916
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14746
Telomerase reverse transcriptase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Telomerase reverse transcriptase is the right protein anchor across sources, using UniProt O14746 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anemia is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTelomerase reverse transcriptase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO14746
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTelomerase reverse transcriptase
UniProt AccessionO14746
Component TypeProtein
Sequence Length1132 aa

Telomerase reverse transcriptase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Telomerase reverse transcriptase, mapped to UniProt O14746. Sequence length is 1132 aa.

Mapped IDO14746
Review nameTelomerase reverse transcriptase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Telomerase reverse transcriptase shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugIMETELSTAT SODIUM
Late clinical Phase III
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugIMETELSTAT
Linked drugIMETELSTAT SODIUM
Late clinical Phase III
myelofibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugIMETELSTAT
Clinical signal Phase II
breast cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugIMETELSTAT
Linked drugIMETELSTAT SODIUM
Clinical signal Phase II
multiple myeloma
2 linked drugs · 2 direct · 2 efficacy
Linked drugIMETELSTAT
Linked drugIMETELSTAT SODIUM
Clinical signal Phase II
essential thrombocythemia
1 linked drug · 1 direct · 1 efficacy
Linked drugIMETELSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anemia because it currently carries approved-linked support. Linked drugs include IMETELSTAT SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
3
Phase III
5
Phase II
Assay Mix

Activity Type Distribution

IC501,012.0
EC50147.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL443683 9.19 IC50 0.64 Preclinical
CHEMBL259739 8.82 IC50 1.5 Preclinical
CHEMBL337762 8.7 EC50 2.0 Preclinical
CHEMBL3347538 8.3 IC50 5.0 Preclinical
CHEMBL3948172 7.9 IC50 12.6 Preclinical
CHEMBL140180 7.75 EC50 18.0 Preclinical
CHEMBL44130 7.75 EC50 18.0 Preclinical
CHEMBL1078511 7.75 IC50 18.0 Preclinical
CHEMBL140180 7.75 IC50 18.0 Preclinical
CHEMBL139511 7.7 EC50 20.0 Preclinical
Distribution

pChEMBL Value Distribution

245
5.0
186
5.5
127
6.0
95
6.5
64
7.0
22
7.5
1
8.0
3
8.5
3
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

380
Total Assays
753
Tested Compounds
2
Assay Types
Binding — 378 assays, 753 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 241 416 5.6
single protein format 109 331 5.7
subcellular format 15 0 —
assay format 10 3 6.1
tissue-based format 3 3 5.7
Functional — 2 assays, 13 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 13 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine